US2013323299A1PendingUtilityA1
Method of inducing neutralizing antibodies to human immunodeficiency virus
Est. expiryApr 12, 2025(expired)· nominal 20-yr term from priority
A61P 37/04A61P 31/18C07K 16/1145A61K 39/12A61K 2039/55561A61K 39/21A61K 2039/55566C12N 2740/16011C12N 2740/16111A61K 2039/55555A61K 39/385C12N 7/00A61K 2039/55505C12N 2740/16122C12N 2740/16134C07K 14/005C07K 16/18C07K 2317/76A61K 39/0005A61K 9/127A61K 2039/57A61K 2039/6018C07K 2319/00Y02A50/30
60
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates, in general, to human immunodeficiency virus (HIV), and, in particular, to a method of inducing neutralizing antibodies to HIV and to compounds and compositions suitable for use in such a method.
Claims
exact text as granted — not AI-modified1 - 32 . (canceled)
33 . A method of inducing the production in a patient of anti-HIV antibodies comprising administering to a patient in need thereof an amount of at least one liposome-peptide conjugate in an amount sufficient to effect said induction, wherein said peptide comprises a membrane external proximal region (MPER) epitope.
34 . The method according to claim 33 wherein said peptide comprises the sequence ELDKWAS or WFNITNW.
35 . The method according to claim 33 wherein said liposome-peptide conjugate comprises a hydrophobic linker.
36 . An immunogen comprising an MPER epitope embedded in a liposome.
37 . The immunogen according to claim 36 bound to a detectable label.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.